Younger Adults with HIV Experience Shorter Times to Viral Rebound

A Canadian study found that a patient’s age was a factor in HIV viral rebound after suppression with treatment, with younger adults experiencing lower prevalence of viral suppression and shorter time to viral rebound than older adults.

“There is an age effect,” principle investigator Robert Hogg, MSc, PhD, British Columbia Centre for Excellence in HIV/AIDS, Vancouver, and Simon Fraser University, Burnaby, British Columbia, Canada, told MD Magazine¨. “However, I think the important point here is that specific subpopulations at all ages are more at risk of not suppressing, or rebounding if they do, than the other people in the cohort,” Hogg said.

Hogg and colleagues in the Canadian Observational Cohort (CANOC) Collaboration have investigated several socio-demographic factors to determine whether any might predict or contribute to HIV viral suppression and rebound, including having compared indigenous and non-indigenous Canadian populations infected with HIV.

In the present study, the researchers sought to distinguish between adults ≤29 years of age and older adults for prevalence and correlates of viral suppression. They identified 9031 HIV-positive adults in 3 of Canada’s most populous provinces, including 1281 individuals ≤29 years of age, who had initiated antiretroviral therapy between 2008-2011 or 2012-2013.

The researchers defined viral suppression and rebound from at least 2 consecutive viral load measurements of <50 or >50 HIV-1 RNA copies/ml, respectively, at least 30 days apart, in a 1-year follow-up period. Of the participants, 477 were excluded for not meeting these criteria, but the number excluded was not significantly different between age groups.

Factors considered as possible covariates of suppression and rebound included age, sex, province of residence, ethnicity, and behavioral transmission risk category. Clinical variables included hepatitis C virus (HCV) co-infection (ever), presence of AIDS symptoms, baseline CD4 cell count, and HIV plasma viral load. Treatment factors included the “era” of initial antiretroviral treatment and the particular regimen.

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below